TickerFacts.

Gossamer Bio, Inc. (GOSS): Revenue

Annual figures by period end, from SEC filings.

$48.47M
Year ended 2025-12-31
$53.29M
Trailing 12 months to 2026-06-30
$114.70M2022-12-31: $02023-12-31: $02024-12-31: $114.70M2025-12-31: $48.47M$48.47M
2022-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$48.47M-57.7%2026-03-17, From 2025-01-01
2024-12-31$114.70Mn/a2026-03-17, From 2024-01-01
2023-12-31$0n/a2026-03-17, From 2023-01-01
2022-12-31$0n/a2025-03-13, From 2022-01-01

Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Gossamer Bio, Inc. (GOSS)2025-12-31$48.47M-57.7%
Lexicon Pharmaceuticals, Inc. (LXRX)2025-12-31$49.80M+60.2%
Protagonist Therapeutics, Inc (PTGX)2025-12-31$46.02M-89.4%
Septerna, Inc. (SEPN)2025-12-31$45.95Mn/m
Ocular Therapeutix, Inc (OCUL)2025-12-31$51.95M-18.5%
Aquestive Therapeutics, Inc. (AQST)2025-12-31$44.55M-22.6%
Cumberland Pharmaceuticals Inc (CPIX)2025-12-31$44.52M+17.6%
Integrated Biopharma Inc (INBP)2026-06-30$43.87M-19.3%
Xilio Therapeutics, Inc. (XLO)2025-12-31$43.77M+589.9%

Compare GOSS, LXRX, PTGX, SEPN side by side · Screen every company in Pharmaceutical Preparations ↗